KR20250027777A - 암을 치료하기 위한 kras g12c 억제제 - Google Patents

암을 치료하기 위한 kras g12c 억제제 Download PDF

Info

Publication number
KR20250027777A
KR20250027777A KR1020257002609A KR20257002609A KR20250027777A KR 20250027777 A KR20250027777 A KR 20250027777A KR 1020257002609 A KR1020257002609 A KR 1020257002609A KR 20257002609 A KR20257002609 A KR 20257002609A KR 20250027777 A KR20250027777 A KR 20250027777A
Authority
KR
South Korea
Prior art keywords
kras
pharmaceutically acceptable
acceptable salt
dose
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257002609A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 마이클 하이먼
슈에치안 공
셩-빈 펑
총 시
멜린다 데일 윌라드
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20250027777A publication Critical patent/KR20250027777A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020257002609A 2022-06-30 2023-06-29 암을 치료하기 위한 kras g12c 억제제 Pending KR20250027777A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263357227P 2022-06-30 2022-06-30
US63/357,227 2022-06-30
US202363486785P 2023-02-24 2023-02-24
US63/486,785 2023-02-24
US202363496447P 2023-04-17 2023-04-17
US63/496,447 2023-04-17
PCT/US2023/026554 WO2024006424A1 (en) 2022-06-30 2023-06-29 Kras g12c inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
KR20250027777A true KR20250027777A (ko) 2025-02-27

Family

ID=87468549

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257002609A Pending KR20250027777A (ko) 2022-06-30 2023-06-29 암을 치료하기 위한 kras g12c 억제제

Country Status (10)

Country Link
US (1) US20240108618A1 (https=)
EP (1) EP4547251A1 (https=)
JP (2) JP7496917B2 (https=)
KR (1) KR20250027777A (https=)
CN (1) CN119907671A (https=)
CA (1) CA3260047A1 (https=)
IL (1) IL317823A (https=)
MA (1) MA71325A (https=)
MX (1) MX2025000105A (https=)
WO (1) WO2024006424A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
ES2929700T3 (es) 2019-12-11 2022-12-01 Lilly Co Eli Inhibidores de KRas g12c
BR112022022021A2 (pt) * 2020-04-30 2022-12-13 Genentech Inc Anticorpos, ácido(s) nucleico(s), vetor, célula hospedeira, processo para produzir um anticorpo, métodos para rastrear um anticorpo, detectar kras-gdp, obter um inibidor, detectar a alquilação de kras, tratar um câncer, rastrear compostos, medir a ligação de uma proteína e medir o engajamento do alvo de um inibidor, kit, chaperona de cristalização, método de cristalização e superfície de biossensor
US20230285498A1 (en) * 2020-08-07 2023-09-14 City Of Hope Treatments for cancers having kras mutations
MX2023003060A (es) * 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
EP4486345A1 (en) * 2022-03-04 2025-01-08 Eli Lilly and Company Method of treatment including kras g12c inhibitors and shp2 inhibitors

Also Published As

Publication number Publication date
MA71325A (fr) 2025-04-30
JP7496917B2 (ja) 2024-06-07
CN119907671A (zh) 2025-04-29
US20240108618A1 (en) 2024-04-04
CA3260047A1 (en) 2024-01-04
AU2023297941A1 (en) 2025-01-16
MX2025000105A (es) 2025-02-10
JP2024007504A (ja) 2024-01-18
WO2024006424A1 (en) 2024-01-04
JP2024112968A (ja) 2024-08-21
IL317823A (en) 2025-02-01
TW202421145A (zh) 2024-06-01
EP4547251A1 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
JP7496917B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン
JP7490635B2 (ja) Ｅｇｆｒ変異がんの処置
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
JP6805336B2 (ja) 薬学的組み合わせ
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
KR20240074779A (ko) 약학적 조성물 및 이의 용도
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
WO2021190637A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
KR102936318B1 (ko) 소세포폐암의 병용 치료용 퀴놀린 유도체
US20230173067A1 (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
JP2023537676A (ja) トラスツズマブ、タキサン及びｖｅｇｆｒ－２アンタゴニストと組み合わせたツカチニブによりｈｅｒ２陽性癌を治療する方法
CN111386117A (zh) 治疗癌症的组合物和方法
JP2024539476A (ja) 医薬組成物およびその使用
CN107949401A (zh) 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物
EP4159238A1 (en) Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
CN115038447A (zh) 用于治疗癌症的组合疗法
TWI921668B (zh) Kras g12c抑制劑之給藥方案
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
AU2023297941B2 (en) Kras g12c inhibitor for treating cancer
US12611403B2 (en) Combined pharmaceutical composition of c-Met kinase inhibitor and anti-PD-L1 antibody
WO2019096233A1 (zh) 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途
Scarpitta et al. Pharmacological Phase I Clinical Trials in Pediatric Brain Tumors (1990–2024): A Historical Perspective
JP2025524957A (ja) 抗ＧＡＲＰ－ＴＧＦ－β１／ＰＤ－１併用療法
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
TW202608446A (zh) 依維替定（ｅｃｕｂｅｃｔｅｄｉｎ）於包括與阿替利珠單抗的組合療法之癌症的治療中之用途

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20250123

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250123

Comment text: Request for Examination of Application

PG1501 Laying open of application